Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.

•Bevacizumab with dose-dense paclitaxel and carboplatin has acceptable toxicity.•Dose-delay is expected but majority complete therapy without growth factor support.•Changes in Flt-3L may represent a biomarker to response to therapy.